Rigel Price Book Value Ratio from 2010 to 2024

RIGL Stock  USD 0.98  0.04  4.26%   
Rigel Pharmaceuticals Price Book Value Ratio yearly trend continues to be quite stable with very little volatility. Price Book Value Ratio may rise above -8.37 this year. From the period between 2010 and 2024, Rigel Pharmaceuticals, Price Book Value Ratio regression line of its data series had sample variance of  78.94 and sample variance of  78.94. View All Fundamentals
 
Price Book Value Ratio  
First Reported
2010-12-31
Previous Quarter
(8.81)
Current Value
(8.37)
Quarterly Volatility
8.88464852
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Rigel Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rigel main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 7.2 M or Total Revenue of 122.7 M, as well as many exotic indicators such as Price To Sales Ratio of 2.05, Dividend Yield of 0.0 or Days Sales Outstanding of 63.95. Rigel financial statements analysis is a perfect complement when working with Rigel Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Rigel Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Rigel Pharmaceuticals Technical models . Check out the analysis of Rigel Pharmaceuticals Correlation against competitors.
For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.

Latest Rigel Pharmaceuticals' Price Book Value Ratio Growth Pattern

Below is the plot of the Price Book Value Ratio of Rigel Pharmaceuticals over the last few years. It is Rigel Pharmaceuticals' Price Book Value Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rigel Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Price Book Value Ratio10 Years Trend
Pretty Stable
   Price Book Value Ratio   
       Timeline  

Rigel Price Book Value Ratio Regression Statistics

Arithmetic Mean1.83
Coefficient Of Variation485.46
Mean Deviation5.70
Median2.93
Standard Deviation8.88
Sample Variance78.94
Range36.3515
R-Value(0.25)
Mean Square Error79.68
R-Squared0.06
Significance0.37
Slope(0.50)
Total Sum of Squares1,105

Rigel Price Book Value Ratio History

2024 -8.37
2023 -8.81
2022 -18.99
2021 14.87
2020 17.36
2019 6.66
2018 3.36

About Rigel Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Rigel Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Rigel Pharmaceuticals investors use historical funamental indicators, such as Rigel Pharmaceuticals's Price Book Value Ratio, to determine how well the company is positioned to perform in the future. Although Rigel Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Rigel Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Rigel Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Rigel Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Rigel Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price Book Value Ratio(8.81)(8.37)

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Rigel Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Rigel Pharmaceuticals is a strong investment it is important to analyze Rigel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rigel Pharmaceuticals' future performance. For an informed investment choice regarding Rigel Stock, refer to the following important reports:
Check out the analysis of Rigel Pharmaceuticals Correlation against competitors.
For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.
Note that the Rigel Pharmaceuticals information on this page should be used as a complementary analysis to other Rigel Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Rigel Stock analysis

When running Rigel Pharmaceuticals' price analysis, check to measure Rigel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rigel Pharmaceuticals is operating at the current time. Most of Rigel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rigel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rigel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rigel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Global Correlations
Find global opportunities by holding instruments from different markets
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Is Rigel Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.48)
Earnings Share
(0.11)
Revenue Per Share
0.684
Quarterly Revenue Growth
0.133
Return On Assets
(0.08)
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.